Skip to main content

Table 2 The top three answers for each qualitative question

From: Management of people with epilepsy during the COVID-19 pandemic: a national survey among epileptologists in China

Items  Responders
(N = 130)
What are the causes of seizure aggravation or increased frequency in patients for case review?
 Withdrawal, decreased dosage, alternative ASMs, and ASMs shortage, n (%) 106 (81.5)
 Lifestyle change, n (%) 35 (26.9)
 Psychological disorders (anxiety and fear), n (%) 24 (18.5)
What are the reasons for the aggravation of psychological disorders (e.g. anxiety or depression) in patients for case review?
 ASMs unavailability; ASMs shortage, n (%) 71 (54.6)
 Fear of suffering from COVID-19, n (%) 53 (40.8)
 Irregular lifestyle, n (%) 19 (14.6)
Why didn’t the patients come for regular case review albeit they should?
 Quarantine and the traffic restrictions, n (%) 96 (73.8)
 Fear of suffering from COVID-19, n (%) 44 (33.8)
 Epidemic of COVID-19, n (%) 20 (15.4)
Why were the patients unable to obtain ASMs?
 Breakdown of ASMs supply systems, n (%) 67 (51.5)
 Quarantine and traffic restrictions, n (%) 62 (47.7)
 Suspension and limitations of clinical services, n (%) 9 (6.9)
What are the urgent needs for people with epilepsy in this COVID-19 crisis?
 Maintaining regular ASMs supply, n (%) 97 (74.6)
 Providing consultation, especially ASMs treatment instruction, n (%) 90 (69.2)
 Psychological counsultation, n (%) 38 (29.2)
  1. ASMs antiseizure medications, COVID-19 coronavirus disease 2019